A project to collect and analyze data on sarcoma patients
A Prospective Registry Study on Biological Disease Profile, Intervention Type and Clinical Outcome in Adolescent and Adult Patients With Soft-tissue and Bone Sarcoma
This study is collecting and analyzing information from sarcoma patients to help improve understanding and treatment of this type of cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 12 Years and up |
| Sex | All |
| Sponsor | University Hospital Heidelberg Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Heidelberg, Baden-Wurttemberg) |
| Trial ID | NCT04758325 on ClinicalTrials.gov |
What this trial studies
The Sarcoma Biology and Outcome Project (SarcBOP) is an observational registry designed to create a comprehensive database that encompasses various aspects of sarcoma treatment and research. It collects clinical, pathologic, and radiologic information, along with multi-layered molecular data and patient-reported outcomes. The project integrates with the clinical activities of the Heidelberg Sarcoma Center and includes a dedicated biobank for tissue samples and liquid biopsies, aiming to provide valuable resources for clinicians and researchers. By continuously updating this database, SarcBOP seeks to enhance understanding and treatment of sarcomas.
Who should consider this trial
Good fit: Ideal candidates for this project are individuals aged 12 years and older with a suspected or proven diagnosis of soft-tissue or bone sarcoma.
Not a fit: Patients with severe neurological or psychiatric disorders that impede their ability to provide informed consent may not benefit from this project.
Why it matters
Potential benefit: If successful, this project could significantly improve the understanding and treatment options for patients with sarcoma.
How similar studies have performed: Other studies focusing on comprehensive data collection in rare diseases have shown promise, indicating that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Suspected or proven diagnosis of soft-tissue or bone sarcoma (STBS) * Age ≥12 years * Ability to understand nature and individual consequences of the registry * Written informed consent * Subjects who are physically or mentally capable of giving consent Exclusion Criteria: • Severe neurological or psychiatric disorder interfering with the ability to give written informed consent
Where this trial is running
Heidelberg, Baden-Wurttemberg
- National Center for Tumour Diseases, University Hospital Heidelberg — Heidelberg, Baden-Wurttemberg, Germany (Recruiting)
Study contacts
- Principal investigator: Richard F. Schlenk, Prof.Dr.med — National Center for Tumour Disease
- Study coordinator: Richard F. Schlenk, Prof.Dr.med
- Email: richard.schlenk@med.uni-heidelberg.de
- Phone: +49 6221 56 6228
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.